The many premium-priced hormonal therapies for prostate cancer present a financial burden for payers. Moreover, costs are set to increase with the recent approvals of the LHRH antagonist Orgovyx…
February 11, 2021
December 23, 2020
Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence…
September 24, 2020
November 27, 2019
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key prostate cancer patient populations covering 171 countries and more than 99%…
June 3, 2019
December 20, 2018
November 12, 2018
December 19, 2017
December 15, 2017
September 20, 2017
October 26, 2016